Compare CVCO & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVCO | ALKS |
|---|---|---|
| Founded | 1965 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.5B |
| IPO Year | 1994 | 2012 |
| Metric | CVCO | ALKS |
|---|---|---|
| Price | $536.73 | $34.24 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 14 |
| Target Price | ★ $550.00 | $43.43 |
| AVG Volume (30 Days) | 126.0K | ★ 2.3M |
| Earning Date | 05-21-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.74 | N/A |
| EPS | ★ 18.55 | 1.43 |
| Revenue | ★ $2,142,713,000.00 | $1,475,899,000.00 |
| Revenue This Year | $14.66 | $24.26 |
| Revenue Next Year | $7.70 | $4.47 |
| P/E Ratio | $28.94 | ★ $23.70 |
| Revenue Growth | ★ 31.68 | N/A |
| 52 Week Low | $393.53 | $25.17 |
| 52 Week High | $713.01 | $36.48 |
| Indicator | CVCO | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 57.97 | 58.27 |
| Support Level | $488.88 | $27.48 |
| Resistance Level | $548.97 | $35.25 |
| Average True Range (ATR) | 14.50 | 0.96 |
| MACD | 4.30 | -0.12 |
| Stochastic Oscillator | 75.41 | 56.72 |
Cavco Industries Inc designs and produces factory-built homes under the Cavco Homes, Fleetwood Homes, and Palm Harbor Homes brands. It also produces modular homes, park model homes, and vacation cabins, as well as commercial structures, among others. The company operates principally in two segments: Factory-built housing, which includes wholesale and retail systems-built housing operations, and the Financial services segment, which includes manufactured housing consumer finance and insurance. Cavco receives a majority of its revenue from the Factory-built housing segment.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.